Critical Milestones Loom for Arrowhead Pharmaceuticals

Regulatory Catalysts Approach

Arrowhead Pharmaceuticals stands at a pivotal juncture, with two significant regulatory developments poised to shape its commercial future. The biotechnology firm is advancing preparations for its first commercial drug launch while simultaneously progressing another innovative therapy through clinical pipelines.

The company faces a decisive FDA PDUFA date for Plozasiran on November 18, representing Arrowhead’s potential breakthrough into commercial markets. This therapeutic candidate targets familial chylomicronemia syndrome (FCS), a rare metabolic disorder.

Concurrently, Arrowhead has achieved another clinical milestone with the October 7 submission of ARO-DIMER-PA for regulatory approval. This novel RNA interference therapy addresses mixed hyperlipidemia and marks the first dual-functional RNAi treatment of its kind in development.

Financial Foundation Supports Operations